Diabetes mellitus type 2

Last updated

Diabetes mellitus type 2
Other namesNoninsulin-dependent diabetes mellitus (NIDDM), adult-onset diabetes [1]
Blue circle for diabetes.svg
Universal blue circle symbol for diabetes [2]
Specialty Endocrinology
Symptoms Increased thirst, frequent urination, unexplained weight loss, increased hunger [3]
Complications Hyperosmolar hyperglycemic state, diabetic ketoacidosis, heart disease, strokes, diabetic retinopathy, kidney failure, amputations [1] [4] [5]
Usual onsetMiddle or older age [6]
DurationLong term [6]
Causes Obesity, lack of exercise, genetics [1] [6]
Diagnostic method Blood test [3]
PreventionMaintaining normal weight, exercising, eating properly [1]
Treatment Dietary changes, metformin, insulin, bariatric surgery [1] [7] [8] [9]
Prognosis10 year shorter life expectancy [10]
Frequency392 million (2015) [11]

Diabetes mellitus type 2 (also known as type 2 diabetes) is a long-term metabolic disorder that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. [6] Common symptoms include increased thirst, frequent urination, and unexplained weight loss. [3] Symptoms may also include increased hunger, feeling tired, and sores that do not heal. [3] Often symptoms come on slowly. [6] Long-term complications from high blood sugar include heart disease, strokes, diabetic retinopathy which can result in blindness, kidney failure, and poor blood flow in the limbs which may lead to amputations. [1] The sudden onset of hyperosmolar hyperglycemic state may occur; however, ketoacidosis is uncommon. [4] [5]

Metabolic disorder disease that involving errors in metabolic processes of building or degradation of molecules

A metabolic disorder can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive.

Hyperglycemia Too much blood sugar, usually because of diabetes

Hyperglycemia, is a condition in which an excessive amount of glucose circulates in the blood plasma. This is generally a blood sugar level higher than 11.1 mmol/l (200 mg/dl), but symptoms may not start to become noticeable until even higher values such as 15–20 mmol/l (~250–300 mg/dl). A subject with a consistent range between ~5.6 and ~7 mmol/l is considered slightly hyperglycemic, while above 7 mmol/l is generally held to have diabetes. For diabetics, glucose levels that are considered to be too hyperglycemic can vary from person to person, mainly due to the person's renal threshold of glucose and overall glucose tolerance. On average however, chronic levels above 10–12 mmol/L can produce noticeable organ damage over time.

Insulin resistance (IR) is considered as a pathological condition in which cells fail to respond normally to the hormone insulin. To prevent hyperglycemia and noticeable organ damage over time, the body produces insulin when glucose starts to be released into the bloodstream, primarily from the digestion of carbohydrates in the diet. Under normal conditions of insulin reactivity, this insulin response triggers glucose being taken into body cells, to be used for energy, and inhibits the body from using fat for energy, thereby causing the concentration of glucose in the blood to decrease as a result, staying within the normal range even when a large amount of carbohydrates is consumed. Carbohydrates comprise simple sugars, i.e. monosaccharides, such as glucose and fructose, disaccharides, such as cane sugar, and polysaccharides, e.g. starches. Fructose, which is metabolised into triglycerides in the liver, stimulates insulin production through another mechanism, and can have a more potent effect than other carbohydrates. A habitually high intake of carbohydrates, and particularly fructose, e.g. with sweetened beverages, contributes to insulin resistance and has been linked to weight gain and obesity. If excess blood sugar is not sufficiently absorbed by cells even in the presence of insulin, the increase in the level of blood sugar can result in the classic hyperglycemic triad of polyphagia, polydipsia, and polyuria. Avoiding carbohydrates and sugars, a no-carbohydrate diet or fasting can reverse insulin resistance.


Type 2 diabetes primarily occurs as a result of obesity and lack of exercise. [1] Some people are more genetically at risk than others. [6] Type 2 diabetes makes up about 90% of cases of diabetes, with the other 10% due primarily to diabetes mellitus type 1 and gestational diabetes. [1] In diabetes mellitus type 1 there is a lower total level of insulin to control blood glucose, due to an autoimmune induced loss of insulin-producing beta cells in the pancreas. [12] [13] Diagnosis of diabetes is by blood tests such as fasting plasma glucose, oral glucose tolerance test, or glycated hemoglobin (A1C). [3]

Obesity medical condition in which excess body fat harms health

Obesity is a medical condition in which excess body fat has accumulated to an extent that it may have a negative effect on health. People are generally considered obese when their body mass index (BMI), a measurement obtained by dividing a person's weight by the square of the person's height, is over 30 kg/m2; the range 25–30 kg/m2 is defined as overweight. Some East Asian countries use lower values. Obesity increases the likelihood of various diseases and conditions, particularly cardiovascular diseases, type 2 diabetes, obstructive sleep apnea, certain types of cancer, osteoarthritis, and depression.

Heredity Passing of traits to offspring from its parents or ancestor

Heredity is the passing on of traits from parents to their offspring, either through asexual reproduction or sexual reproduction, the offspring cells or organisms acquire the genetic information of their parents. Through heredity, variations between individuals can accumulate and cause species to evolve by natural selection. The study of heredity in biology is genetics.

Diabetes mellitus type 1 form of diabetes mellitus

Diabetes mellitus type 1, also known as juvenile diabetes, is a form of diabetes mellitus in which very little or no insulin is produced by the pancreas. Before treatment this results in high blood sugar levels in the body. The classic symptoms are frequent urination, increased thirst, increased hunger, and weight loss. Additional symptoms may include blurry vision, feeling tired, and poor wound healing. Symptoms typically develop over a short period of time.

Type 2 diabetes is partly preventable by staying a normal weight, exercising regularly, and eating properly. [1] Treatment involves exercise and dietary changes. [1] If blood sugar levels are not adequately lowered, the medication metformin is typically recommended. [7] [14] Many people may eventually also require insulin injections. [9] In those on insulin, routinely checking blood sugar levels is advised; however, this may not be needed in those taking pills. [15] Bariatric surgery often improves diabetes in those who are obese. [8] [16]

A diabetic diet is a diet that is used by people with diabetes mellitus or high blood glucose to minimize symptoms and dangerous consequences of the disease.

Metformin chemical compound

Metformin, marketed under the trade name Glucophage among others, is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. Limited evidence suggests metformin may prevent the cardiovascular disease and cancer complications of diabetes. It is not associated with weight gain. It is taken by mouth.

Bariatric surgery includes a variety of procedures performed on people who have obesity. Weight loss is achieved by reducing the size of the stomach with a gastric band or through removal of a portion of the stomach or by resecting and re-routing the small intestine to a small stomach pouch.

Rates of type 2 diabetes have increased markedly since 1960 in parallel with obesity. [17] As of 2015 there were approximately 392 million people diagnosed with the disease compared to around 30 million in 1985. [11] [18] Typically it begins in middle or older age, [6] although rates of type 2 diabetes are increasing in young people. [19] [20] Type 2 diabetes is associated with a ten-year-shorter life expectancy. [10] Diabetes was one of the first diseases described. [21] The importance of insulin in the disease was determined in the 1920s. [22]

Signs and symptoms

Overview of the most significant symptoms of diabetes. Main symptoms of diabetes.svg
Overview of the most significant symptoms of diabetes.

The classic symptoms of diabetes are polyuria (frequent urination), polydipsia (increased thirst), polyphagia (increased hunger), and weight loss. [23] Other symptoms that are commonly present at diagnosis include a history of blurred vision, itchiness, peripheral neuropathy, recurrent vaginal infections, and fatigue. [13] Many people, however, have no symptoms during the first few years and are diagnosed on routine testing. [13] A small number of people with type 2 diabetes mellitus can develop a hyperosmolar hyperglycemic state (a condition of very high blood sugar associated with a decreased level of consciousness and low blood pressure). [13]

Polyuria excessive or abnormally large production or passage of urine

Polyuria is excessive or an abnormally large production or passage of urine. Frequent urination is usually an accompanying symptom. Increased production and passage of urine may also be termed diuresis. Polyuria often appears in conjunction with polydipsia, though it is possible to have one without the other, and the latter may be a cause or an effect. Psychogenic polydipsia may lead to polyuria. Polyuria is usually viewed as a symptom or sign of another disorder, but it can be classed as a disorder, at least when its underlying causes are not clear.

Polydipsia is excessive thirst or excess drinking. The word derives from the Greek πολυδίψιος (poludípsios) "very thirsty", which is derived from πολύς + δίψα. Polydipsia is a nonspecific symptom in various medical disorders. It also occurs as an abnormal behaviour in some non-human animals, such as in birds.

Polyphagia or hyperphagia is excessive hunger or increased appetite.


Type 2 diabetes is typically a chronic disease associated with a ten-year-shorter life expectancy. [10] This is partly due to a number of complications with which it is associated, including: two to four times the risk of cardiovascular disease, including ischemic heart disease and stroke; a 20-fold increase in lower limb amputations, and increased rates of hospitalizations. [10] In the developed world, and increasingly elsewhere, type 2 diabetes is the largest cause of nontraumatic blindness and kidney failure. [24] It has also been associated with an increased risk of cognitive dysfunction and dementia through disease processes such as Alzheimer's disease and vascular dementia. [25] Other complications include acanthosis nigricans, sexual dysfunction, and frequent infections. [23]

Cardiovascular disease class of diseases that involve the heart or blood vessels

Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. CVD includes coronary artery diseases (CAD) such as angina and myocardial infarction. Other CVDs include stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.

Stroke Medical condition where poor blood flow to the brain causes cell death

A stroke is a medical condition in which poor blood flow to the brain results in cell death. There are two main types of stroke: ischemic, due to lack of blood flow, and hemorrhagic, due to bleeding. Both result in parts of the brain not functioning properly. Signs and symptoms of a stroke may include an inability to move or feel on one side of the body, problems understanding or speaking, dizziness, or loss of vision to one side. Signs and symptoms often appear soon after the stroke has occurred. If symptoms last less than one or two hours it is known as a transient ischemic attack (TIA) or mini-stroke. A hemorrhagic stroke may also be associated with a severe headache. The symptoms of a stroke can be permanent. Long-term complications may include pneumonia or loss of bladder control.

Chronic kidney disease progressive loss in kidney function over a period of months or years

Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney function over a period of months or years. Early on there are typically no symptoms. Later, leg swelling, feeling tired, vomiting, loss of appetite, or confusion may develop. Complications may include heart disease, high blood pressure, bone disease, or anemia.


The development of type 2 diabetes is caused by a combination of lifestyle and genetic factors. [24] [26] While some of these factors are under personal control, such as diet and obesity, other factors are not, such as increasing age, female gender, and genetics. [10] Obesity is more common in women than men in many parts of Africa. [27] A lack of sleep has been linked to type 2 diabetes. [28] This is believed to act through its effect on metabolism. [28] The nutritional status of a mother during fetal development may also play a role, with one proposed mechanism being that of DNA methylation. [29] The intestinal bacteria Prevotella copri and Bacteroides vulgatus have been connected with type 2 diabetes. [30]


Lifestyle factors are important to the development of type 2 diabetes, including obesity and being overweight (defined by a body mass index of greater than 25), lack of physical activity, poor diet, stress, and urbanization. [10] [31] Excess body fat is associated with 30% of cases in those of Chinese and Japanese descent, 60–80% of cases in those of European and African descent, and 100% of cases in Pima Indians and Pacific Islanders. [13] Among those who are not obese, a high waist–hip ratio is often present. [13] Smoking appears to increase the risk of type 2 diabetes mellitus. [32]

Dietary factors also influence the risk of developing type 2 diabetes. Consumption of sugar-sweetened drinks in excess is associated with an increased risk. [33] [34] The type of fats in the diet are important, with saturated fats and trans fatty acids increasing the risk, and polyunsaturated and monounsaturated fat decreasing the risk. [26] Eating a lot of white rice appears to play a role in increasing risk. [35] A lack of exercise is believed to cause 7% of cases. [36] Persistent organic pollutants may play a role. [37]


Most cases of diabetes involve many genes, with each being a small contributor to an increased probability of becoming a type 2 diabetic. [10] If one identical twin has diabetes, the chance of the other developing diabetes within his lifetime is greater than 90%, while the rate for nonidentical siblings is 25–50%. [13] As of 2011, more than 36 genes had been found that contribute to the risk of type 2 diabetes. [38] All of these genes together still only account for 10% of the total heritable component of the disease. [38] The TCF7L2 allele, for example, increases the risk of developing diabetes by 1.5 times and is the greatest risk of the common genetic variants. [13] Most of the genes linked to diabetes are involved in beta cell functions. [13]

There are a number of rare cases of diabetes that arise due to an abnormality in a single gene (known as monogenic forms of diabetes or "other specific types of diabetes"). [10] [13] These include maturity onset diabetes of the young (MODY), Donohue syndrome, and Rabson–Mendenhall syndrome, among others. [10] Maturity onset diabetes of the young constitute 1–5% of all cases of diabetes in young people. [39]

Medical conditions

There are a number of medications and other health problems that can predispose to diabetes. [40] Some of the medications include: glucocorticoids, thiazides, beta blockers, atypical antipsychotics, [41] and statins. [42] Those who have previously had gestational diabetes are at a higher risk of developing type 2 diabetes. [23] Other health problems that are associated include: acromegaly, Cushing's syndrome, hyperthyroidism, pheochromocytoma, and certain cancers such as glucagonomas. [40] Testosterone deficiency is also associated with type 2 diabetes. [43] [44]


Insulin resistance (right side) contributes to high glucose levels in the blood. Type 2 Diabetes Mellitus.jpg
Insulin resistance (right side) contributes to high glucose levels in the blood.

Type 2 diabetes is due to insufficient insulin production from beta cells in the setting of insulin resistance. [13] Insulin resistance, which is the inability of cells to respond adequately to normal levels of insulin, occurs primarily within the muscles, liver, and fat tissue. [45] In the liver, insulin normally suppresses glucose release. However, in the setting of insulin resistance, the liver inappropriately releases glucose into the blood. [10] The proportion of insulin resistance versus beta cell dysfunction differs among individuals, with some having primarily insulin resistance and only a minor defect in insulin secretion and others with slight insulin resistance and primarily a lack of insulin secretion. [13]

Other potentially important mechanisms associated with type 2 diabetes and insulin resistance include: increased breakdown of lipids within fat cells, resistance to and lack of incretin, high glucagon levels in the blood, increased retention of salt and water by the kidneys, and inappropriate regulation of metabolism by the central nervous system. [10] However, not all people with insulin resistance develop diabetes, since an impairment of insulin secretion by pancreatic beta cells is also required. [13]


WHO diabetes diagnostic criteria [46] [47]   edit
Condition2-hour glucoseFasting glucoseHbA1c
Unitmmol/l(mg/dl)mmol/l(mg/dl)mmol/molDCCT %
Normal<7.8 (<140)<6.1 (<110)<42<6.0
Impaired fasting glycaemia <7.8 (<140)≥6.1(≥110) & <7.0(<126)42-466.0–6.4
Impaired glucose tolerance ≥7.8 (≥140)<7.0 (<126)42-466.0–6.4
Diabetes mellitus ≥11.1 (≥200)≥7.0 (≥126)≥48≥6.5

The World Health Organization definition of diabetes (both type 1 and type 2) is for a single raised glucose reading with symptoms, otherwise raised values on two occasions, of either: [48]


A random blood sugar of greater than 11.1 mmol/l (200 mg/dl) in association with typical symptoms [23] or a glycated hemoglobin (HbA1c) of ≥ 48 mmol/mol (≥ 6.5 DCCT %) is another method of diagnosing diabetes. [10] In 2009 an International Expert Committee that included representatives of the American Diabetes Association (ADA), the International Diabetes Federation (IDF), and the European Association for the Study of Diabetes (EASD) recommended that a threshold of ≥ 48 mmol/mol (≥ 6.5 DCCT %) should be used to diagnose diabetes. [49] This recommendation was adopted by the American Diabetes Association in 2010. [50] Positive tests should be repeated unless the person presents with typical symptoms and blood sugars >11.1 mmol/l (>200 mg/dl). [49]

Threshold for diagnosis of diabetes is based on the relationship between results of glucose tolerance tests, fasting glucose or HbA1c and complications such as retinal problems. [10] A fasting or random blood sugar is preferred over the glucose tolerance test, as they are more convenient for people. [10] HbA1c has the advantages that fasting is not required and results are more stable but has the disadvantage that the test is more costly than measurement of blood glucose. [51] It is estimated that 20% of people with diabetes in the United States do not realize that they have the disease. [10]

Diabetes mellitus type 2 is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency. [52] This is in contrast to diabetes mellitus type 1 in which there is an absolute insulin deficiency due to destruction of islet cells in the pancreas and gestational diabetes mellitus that is a new onset of high blood sugars associated with pregnancy. [13] Type 1 and type 2 diabetes can typically be distinguished based on the presenting circumstances. [49] If the diagnosis is in doubt antibody testing may be useful to confirm type 1 diabetes and C-peptide levels may be useful to confirm type 2 diabetes, [53] with C-peptide levels normal or high in type 2 diabetes, but low in type 1 diabetes. [54]


No major organization recommends universal screening for diabetes as there is no evidence that such a program improve outcomes. [55] [56] Screening is recommended by the United States Preventive Services Task Force (USPSTF) in adults without symptoms whose blood pressure is greater than 135/80 mmHg. [57] For those whose blood pressure is less, the evidence is insufficient to recommend for or against screening. [57] There is no evidence that it changes the risk of death in this group of people. [56] They also recommend screening among those who are overweight and between the ages of 40 and 70. [58]

The World Health Organization recommends testing those groups at high risk [55] and in 2014 the USPSTF is considering a similar recommendation. [59] High-risk groups in the United States include: those over 45 years old; those with a first degree relative with diabetes; some ethnic groups, including Hispanics, African-Americans, and Native-Americans; a history of gestational diabetes; polycystic ovary syndrome; excess weight; and conditions associated with metabolic syndrome. [23] The American Diabetes Association recommends screening those who have a BMI over 25 (in people of Asian descent screening is recommended for a BMI over 23). [60]


Onset of type 2 diabetes can be delayed or prevented through proper nutrition and regular exercise. [61] [62] [ needs update ] Intensive lifestyle measures may reduce the risk by over half. [24] [63] The benefit of exercise occurs regardless of the person's initial weight or subsequent weight loss. [64] High levels of physical activity reduce the risk of diabetes by about 28%. [65] Evidence for the benefit of dietary changes alone, however, is limited, [66] with some evidence for a diet high in green leafy vegetables [67] and some for limiting the intake of sugary drinks. [33] There is an association between higher intake of sugar-sweetened fruit juice and diabetes but no evidence of an association with 100% fruit juice. [68] A 2019 review found evidence of benefit from dietary fiber. [69]

In those with impaired glucose tolerance, diet and exercise either alone or in combination with metformin or acarbose may decrease the risk of developing diabetes. [24] [70] Lifestyle interventions are more effective than metformin. [24] A 2017 review found that, long term, lifestyle changes decreased the risk by 28%, while medication does not reduce risk after withdrawal. [71] While low vitamin D levels are associated with an increased risk of diabetes, correcting the levels by supplementing vitamin D3 does not improve that risk. [72]


Management of type 2 diabetes focuses on lifestyle interventions, lowering other cardiovascular risk factors, and maintaining blood glucose levels in the normal range. [24] Self-monitoring of blood glucose for people with newly diagnosed type 2 diabetes may be used in combination with education, [73] although the benefit of self-monitoring in those not using multi-dose insulin is questionable. [24] In those who do not want to measure blood levels, measuring urine levels may be done. [73] Managing other cardiovascular risk factors, such as hypertension, high cholesterol, and microalbuminuria, improves a person's life expectancy. [24] Decreasing the systolic blood pressure to less than 140 mmHg is associated with a lower risk of death and better outcomes. [74] Intensive blood pressure management (less than 130/80 mmHg) as opposed to standard blood pressure management (less than 140-160 mmHg systolic to 85–100 mmHg diastolic) results in a slight decrease in stroke risk but no effect on overall risk of death. [75]

Intensive blood sugar lowering (HbA1c<6%) as opposed to standard blood sugar lowering (HbA1c of 7–7.9%) does not appear to change mortality. [76] [77] The goal of treatment is typically an HbA1c of 7 to 8% or a fasting glucose of less than 7.2 mmol/L (130 mg/dl); however these goals may be changed after professional clinical consultation, taking into account particular risks of hypoglycemia and life expectancy. [60] [78] [79] Despite guidelines recommending that intensive blood sugar control be based on balancing immediate harms with long-term benefits, many people – for example people with a life expectancy of less than nine years who will not benefit, are over-treated. [80]

It is recommended that all people with type 2 diabetes get regular eye examination. [13] There is weak evidence suggesting that treating gum disease by scaling and root planing may result in a small short-term improvement in blood sugar levels for people with diabetes. [81] There is no evidence to suggest that this improvement in blood sugar levels is maintained longer than 4 months. [81] There is also not enough evidence to determine if medications to treat gum disease are effective at lowering blood sugar levels. [81]


A proper diet and exercise are the foundations of diabetic care, [23] with a greater amount of exercise yielding better results. [82] Exercise improves blood sugar control, decreases body fat content and decreases blood lipid levels, and these effects are evident even without weight loss. [83] Aerobic exercise leads to a decrease in HbA1c and improved insulin sensitivity. [84] Resistance training is also useful and the combination of both types of exercise may be most effective. [84]

A diabetic diet that promotes weight loss is important. [85] While the best diet type to achieve this is controversial, [85] a low glycemic index diet or low carbohydrate diet has been found to improve blood sugar control. [86] [87] A very low calorie diet, begun shortly after the onset of type 2 diabetes, can result in remission of the condition. [88]

Vegetarian diets in general have been related to lower diabetes risk, but do not offer advantages compared with diets which allow moderate amounts of animal products. [89] There is not enough evidence to suggest that cinnamon improves blood sugar levels in people with type 2 diabetes. [90]

Culturally appropriate education may help people with type 2 diabetes control their blood sugar levels, for up to 24 months. [91] If changes in lifestyle in those with mild diabetes has not resulted in improved blood sugars within six weeks, medications should then be considered. [23] There is not enough evidence to determine if lifestyle interventions affect mortality in those who already have DM2. [63]


Metformin 500mg tablets. Metformin 500mg Tablets.jpg
Metformin 500mg tablets.

There are several classes of anti-diabetic medications available. Metformin is generally recommended as a first line treatment as there is some evidence that it decreases mortality; [7] [24] [92] however, this conclusion is questioned. [93] Metformin should not be used in those with severe kidney or liver problems. [23]

A second oral agent of another class or insulin may be added if metformin is not sufficient after three months. [78] Other classes of medications include: sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, SGLT2 inhibitors, and glucagon-like peptide-1 analogs. [78] As of 2015 there was no significant difference between these agents. [78] A 2018 review found that SGLT2 inhibitors may be better than glucagon-like peptide-1 analogs or dipeptidyl peptidase-4 inhibitors. [94]

Rosiglitazone, a thiazolidinedione, has not been found to improve long-term outcomes even though it improves blood sugar levels. [95] Additionally it is associated with increased rates of heart disease and death. [96] Angiotensin-converting enzyme inhibitors (ACEIs) prevent kidney disease and improve outcomes in those with diabetes. [97] [98] The similar medications angiotensin receptor blockers (ARBs) do not. [98] A 2016 review recommended treating to a systolic blood pressure of 140 to 150 mmHg. [99]

Injections of insulin may either be added to oral medication or used alone. [24] Most people do not initially need insulin. [13] When it is used, a long-acting formulation is typically added at night, with oral medications being continued. [23] [24] Doses are then increased to effect (blood sugar levels being well controlled). [24] When nightly insulin is insufficient, twice daily insulin may achieve better control. [23] The long acting insulins glargine and detemir are equally safe and effective, [100] and do not appear much better than neutral protamine Hagedorn (NPH) insulin, but as they are significantly more expensive, they are not cost effective as of 2010. [101] In those who are pregnant insulin is generally the treatment of choice. [23]

Vitamin D supplementation to people with type 2 diabetes may improve markers of insulin resistance and HbA1c. [102]


Weight loss surgery in those who are obese is an effective measure to treat diabetes. [103] Many are able to maintain normal blood sugar levels with little or no medication following surgery [104] and long-term mortality is decreased. [105] There however is some short-term mortality risk of less than 1% from the surgery. [106] The body mass index cutoffs for when surgery is appropriate are not yet clear. [105] It is recommended that this option be considered in those who are unable to get both their weight and blood sugar under control. [107] [108]


Regional rates of diabetes using data from 195 countries in 2014 Prevalence of Diabetes by Percent of Country Population (2014) Gradient Map.png
Regional rates of diabetes using data from 195 countries in 2014

Globally as of 2015 it was estimated that there were 392 million people with type 2 diabetes making up about 90% of diabetes cases. [10] [11] This is equivalent to about 6% of the world's population. [11] Diabetes is common both in the developed and the developing world. [10] It remains uncommon, however, in the least developed countries. [13]

Women seem to be at a greater risk as do certain ethnic groups, [10] [109] such as South Asians, Pacific Islanders, Latinos, and Native Americans. [23] This may be due to enhanced sensitivity to a Western lifestyle in certain ethnic groups. [110] Traditionally considered a disease of adults, type 2 diabetes is increasingly diagnosed in children in parallel with rising obesity rates. [10] Type 2 diabetes is now diagnosed as frequently as type 1 diabetes in teenagers in the United States. [13]

Rates of diabetes in 1985 were estimated at 30 million, increasing to 135 million in 1995 and 217 million in 2005. [18] This increase is believed to be primarily due to the global population aging, a decrease in exercise, and increasing rates of obesity. [18] The five countries with the greatest number of people with diabetes as of 2000 are India having 31.7 million, China 20.8 million, the United States 17.7 million, Indonesia 8.4 million, and Japan 6.8 million. [111] It is recognized as a global epidemic by the World Health Organization. [1]


Diabetes is one of the first diseases described [21] with an Egyptian manuscript from c. 1500 BCE mentioning "too great emptying of the urine." [112] The first described cases are believed to be of type 1 diabetes. [112] Indian physicians around the same time identified the disease and classified it as madhumeha or honey urine noting that the urine would attract ants. [112] The term "diabetes" or "to pass through" was first used in 230 BCE by the Greek Apollonius Of Memphis. [112] The disease was rare during the time of the Roman empire with Galen commenting that he had only seen two cases during his career. [112]

Type 1 and type 2 diabetes were identified as separate conditions for the first time by the Indian physicians Sushruta and Charaka in 400–500 AD with type 1 associated with youth and type 2 with being overweight. [112] The term "mellitus" or "from honey" was added by the Briton John Rolle in the late 1700s to separate the condition from diabetes insipidus which is also associated with frequent urination. [112] Effective treatment was not developed until the early part of the 20th century when the Canadians Frederick Banting and Charles Best discovered insulin in 1921 and 1922. [112] This was followed by the development of the long acting NPH insulin in the 1940s. [112]

Related Research Articles

Metabolic syndrome clustering of medical conditions (giving a total of 16 possible combinations giving the syndrome)

Metabolic syndrome, sometimes known by other names, is a clustering of at least three of the five following medical conditions: central obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL).

Drugs used in diabetes treat diabetes mellitus by lowering the glucose level in the blood. With the exceptions of insulin, exenatide, liraglutide and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, as well as other factors.

Pioglitazone chemical compound

Pioglitazone, sold under the brand name Actos among others, is a medication used to treat diabetes mellitus type 2. It may be used with metformin, a sulfonylurea, or insulin. Use is recommended together with exercise and diet. It is not recommended in diabetes mellitus type 1. It is taken by mouth.

Gestational diabetes condition in which a woman without diabetes develops high blood sugar levels during pregnancy

Gestational diabetes is a condition in which a woman without diabetes develops high blood sugar levels during pregnancy. Gestational diabetes generally results in few symptoms; however, it does increase the risk of pre-eclampsia, depression, and requiring a Caesarean section. Babies born to mothers with poorly treated gestational diabetes are at increased risk of being too large, having low blood sugar after birth, and jaundice. If untreated, it can also result in a stillbirth. Long term, children are at higher risk of being overweight and developing type 2 diabetes.

Sulfonylureas are a class of organic compounds used in medicine and agriculture. They are antidiabetic drugs widely used in the management of diabetes mellitus type 2. They act by increasing insulin release from the beta cells in the pancreas. A number of sulfonylureas are also used as herbicides ("weedkiller"), because they can interfere with plant biosynthesis of certain amino acids. Sulfonylureas are also used experimentally to inhibit interleukin 1 beta release from the NALP3 inflammasome.

Hyperinsulinemia condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose

Hyperinsulinemia, is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. While it is often mistaken for diabetes or hyperglycaemia, hyperinsulinemia can result from a variety of metabolic diseases and conditions. While hyperinsulinemia is often seen in people with early stage type 2 diabetes mellitus, it is not the cause of the condition and is only one symptom of the disease. Type 1 diabetes only occurs when pancreatic beta-cell function is impaired. Hyperinsulinemia can be seen in a variety of conditions including diabetes mellitus type 2, in neonates and in drug induced hyperinsulinemia. It can also occur in congenital hyperinsulism, including nesidioblastosis.

Glibenclamide chemical compound

Glibenclamide, also known as glyburide, is a medication used to treat diabetes mellitus type 2. It is recommended that it be taken together with diet and exercise. It may be used with other antidiabetic medication. It is not recommended for use by itself in diabetes mellitus type 1. It is taken by mouth.

The term diabetes includes several different metabolic disorders that all, if left untreated, result in abnormally high concentration of a sugar called glucose in the blood. Diabetes mellitus type 1 results when the pancreas no longer produces significant amounts of the hormone insulin, usually owing to the autoimmune destruction of the insulin-producing beta cells of the pancreas. Diabetes mellitus type 2, in contrast, is now thought to result from autoimmune attacks on the pancreas and/or insulin resistance. The pancreas of a person with type 2 diabetes may be producing normal or even abnormally large amounts of insulin. Other forms of diabetes mellitus, such as the various forms of maturity onset diabetes of the young, may represent some combination of insufficient insulin production and insulin resistance. Some degree of insulin resistance may also be present in a person with type 1 diabetes.

Sitagliptin chemical compound

Sitagliptin, sold under the brand name Januvia among others, is an medication used to treat diabetes mellitus type 2. It is generally less preferred than metformin or a sulfonylurea. It is taken by mouth. It is also avaliable within a single pill as metformin/sitagliptin.

Prediabetes is the precursor stage before diabetes mellitus in which not all of the symptoms required to diagnose diabetes are present, but blood sugar is abnormally high. This stage is often referred to as the "grey area". It is not a disease; the American Diabetes Association says, "Prediabetes should not be viewed as a clinical entity in its own right but rather as an increased risk for diabetes and cardiovascular disease (CVD). Prediabetes is associated with obesity, dyslipidemia with high triglycerides and/or low HDL cholesterol, and hypertension." It is thus a metabolic diathesis or syndrome, and it usually involves no symptoms and only high blood sugar as the sole sign.

Canagliflozin chemical compound

Canagliflozin, sold under the brand name Invokana among others, is a medication used to treat type 2 diabetes. It less preferred than metformin. It is used together with exercise and diet. It is not recommended in type 1 diabetes. It is taken by mouth.

Empagliflozin, sold under the trade name Jardiance among others, is a medication used together with diet and exercise to treat type 2 diabetes. It is less preferred than metformin and sulfonylureas. It may be used together with other medications such as metformin or insulin. It is not recommended for type 1 diabetes. It is taken by mouth.

Dulaglutide is a glucagon-like peptide-1 receptor agonist consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG4. It is used for the treatment of type 2 diabetes and can be used once weekly. GLP-1 is a hormone that is involved in the normalization of level of glucose in blood (glycemia). The FDA approved dulaglutide for use in the United States in September 2014. The drug is manufactured by Eli Lilly under the brand name Trulicity.

SGLT2 inhibitors, also called gliflozins, are a class of medications that inhibit reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium-glucose transport protein 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type II diabetes mellitus (DM-2). Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in T2DM patients. Several medications of this class have been approved or are currently under development. In studies on canagliflozin, a member of this class, the medication was found to enhance blood sugar control as well as reduce body weight and systolic and diastolic blood pressure.


  1. 1 2 3 4 5 6 7 8 9 10 11 "Diabetes Fact sheet N°312". World Health Organization. August 2011. Archived from the original on 26 August 2013. Retrieved 2012-01-09.
  2. "Diabetes Blue Circle Symbol". International Diabetes Federation. 17 March 2006. Archived from the original on 5 August 2007.
  3. 1 2 3 4 5 "Diagnosis of Diabetes and Prediabetes". National Institute of Diabetes and Digestive and Kidney Diseases. June 2014. Archived from the original on 6 March 2016. Retrieved 10 February 2016.
  4. 1 2 Pasquel FJ, Umpierrez GE (November 2014). "Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment". Diabetes Care. 37 (11): 3124–31. doi:10.2337/dc14-0984. PMC   4207202 . PMID   25342831.
  5. 1 2 Fasanmade OA, Odeniyi IA, Ogbera AO (June 2008). "Diabetic ketoacidosis: diagnosis and management". African Journal of Medicine and Medical Sciences. 37 (2): 99–105. PMID   18939392.
  6. 1 2 3 4 5 6 7 "Causes of Diabetes". National Institute of Diabetes and Digestive and Kidney Diseases. June 2014. Archived from the original on 2 February 2016. Retrieved 10 February 2016.
  7. 1 2 3 Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S (June 2016). "Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis". Annals of Internal Medicine. 164 (11): 740–51. doi:10.7326/M15-2650. PMID   27088241.
  8. 1 2 Cetinkunar S, Erdem H, Aktimur R, Sozen S (June 2015). "Effect of bariatric surgery on humoral control of metabolic derangements in obese patients with type 2 diabetes mellitus: How it works". World Journal of Clinical Cases. 3 (6): 504–9. doi:10.12998/wjcc.v3.i6.504. PMC   4468896 . PMID   26090370.
  9. 1 2 Krentz AJ, Bailey CJ (February 2005). "Oral antidiabetic agents: current role in type 2 diabetes mellitus". Drugs. 65 (3): 385–411. doi:10.2165/00003495-200565030-00005. PMID   15669880.
  10. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Melmed, Shlomo; Polonsky, Kenneth S.; Larsen, P. Reed; Kronenberg, Henry M., eds. (2011). Williams textbook of endocrinology (12th ed.). Philadelphia: Elsevier/Saunders. pp. 1371–1435. ISBN   978-1-4377-0324-5.
  11. 1 2 3 4 Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC   5055577 . PMID   27733282.
  12. MacKay, Ian; Rose, Noel, eds. (2014). The Autoimmune Diseases. Academic Press. p. 575. ISBN   978-0-123-84929-8. OCLC   965646175.
  13. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Gardner, David G.; Shoback, Dolores, eds. (2011). "Chapter 17: Pancreatic hormones & diabetes mellitus". Greenspan's basic & clinical endocrinology (9th ed.). New York: McGraw-Hill Medical. ISBN   978-0-07-162243-1. OCLC   613429053.
  14. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D (July 2005). "Metformin monotherapy for type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews (3): CD002966. doi:10.1002/14651858.CD002966.pub3. PMID   16034881. (Retracted, see doi:10.1002/14651858.cd002966.pub4. If this is an intentional citation to a retracted paper, please replace {{Retracted}} with {{Retracted |intentional=yes}}.)
  15. Malanda UL, Welschen LM, Riphagen II, Dekker JM, Nijpels G, Bot SD (January 2012). "Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin". The Cochrane Database of Systematic Reviews. 1: CD005060. doi:10.1002/14651858.CD005060.pub3. hdl:1871/48558. PMID   22258959.
  16. Ganguly S, Tan HC, Lee PC, Tham KW (April 2015). "Metabolic bariatric surgery and type 2 diabetes mellitus: an endocrinologist's perspective". Journal of Biomedical Research. 29 (2): 105–11. doi:10.7555/JBR.29.20140127. PMC   4389109 . PMID   25859264.
  17. Moscou, Susan (2013). "Getting the word out: advocacy, social marketing, and policy development and enforcement". In Truglio-Londrigan, Marie; Lewenson, Sandra B. (eds.). Public health nursing: practicing population-based care (2nd ed.). Burlington, MA: Jones & Bartlett Learning. p.  317. ISBN   978-1-4496-4660-8. OCLC   758391750.
  18. 1 2 3 Smyth S, Heron A (January 2006). "Diabetes and obesity: the twin epidemics". Nature Medicine. 12 (1): 75–80. doi:10.1038/nm0106-75. PMID   16397575.
  19. Tfayli H, Arslanian S (March 2009). "Pathophysiology of type 2 diabetes mellitus in youth: the evolving chameleon". Arquivos Brasileiros de Endocrinologia e Metabologia. 53 (2): 165–74. doi:10.1590/s0004-27302009000200008. PMC   2846552 . PMID   19466209.
  20. Imperatore G, Boyle JP, Thompson TJ, Case D, Dabelea D, Hamman RF, Lawrence JM, Liese AD, Liu LL, Mayer-Davis EJ, Rodriguez BL, Standiford D (December 2012). "Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth". Diabetes Care. 35 (12): 2515–20. doi:10.2337/dc12-0669. PMC   3507562 . PMID   23173134. Archived from the original on 2016-08-14.
  21. 1 2 Leutholtz BC, Ripoll I (2011). "Diabetes". Exercise and disease management (2nd ed.). Boca Raton: CRC Press. p. 25. ISBN   978-1-4398-2759-8. OCLC   725919496.
  22. Zaccardi F, Webb DR, Yates T, Davies MJ (February 2016). "Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective". Postgraduate Medical Journal. 92 (1084): 63–9. doi:10.1136/postgradmedj-2015-133281. PMID   26621825.
  23. 1 2 3 4 5 6 7 8 9 10 11 12 Vijan S (March 2010). "In the clinic. Type 2 diabetes". Annals of Internal Medicine. 152 (5): ITC31–15, quiz ITC316. doi:10.7326/0003-4819-152-5-201003020-01003. PMID   20194231.
  24. 1 2 3 4 5 6 7 8 9 10 11 12 Ripsin CM, Kang H, Urban RJ (January 2009). "Management of blood glucose in type 2 diabetes mellitus". American Family Physician. 79 (1): 29–36. PMID   19145963.
  25. Pasquier F (October 2010). "Diabetes and cognitive impairment: how to evaluate the cognitive status?". Diabetes & Metabolism. 36 Suppl 3: S100–5. doi:10.1016/S1262-3636(10)70475-4. PMID   21211730.
  26. 1 2 Risérus U, Willett WC, Hu FB (January 2009). "Dietary fats and prevention of type 2 diabetes". Progress in Lipid Research. 48 (1): 44–51. doi:10.1016/j.plipres.2008.10.002. PMC   2654180 . PMID   19032965.
  27. Hilawe, Esayas Haregot; Yatsuya, Hiroshi; Kawaguchi, Leo; Aoyama, Atsuko (1 September 2013). "Differences by sex in the prevalence of diabetes mellitus, impaired fasting glycaemia and impaired glucose tolerance in sub-Saharan Africa: a systematic review and meta-analysis". Bulletin of the World Health Organization. 91 (9): 671–682D. doi:10.2471/BLT.12.113415. PMID   24101783.
  28. 1 2 Touma C, Pannain S (August 2011). "Does lack of sleep cause diabetes?". Cleveland Clinic Journal of Medicine. 78 (8): 549–58. doi:10.3949/ccjm.78a.10165. PMID   21807927.
  29. Christian P, Stewart CP (March 2010). "Maternal micronutrient deficiency, fetal development, and the risk of chronic disease". The Journal of Nutrition. 140 (3): 437–45. doi:10.3945/jn.109.116327. PMID   20071652.
  30. Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, et al. (July 2016). "Human gut microbes impact host serum metabolome and insulin sensitivity". Nature. 535 (7612): 376–81. Bibcode:2016Natur.535..376P. doi:10.1038/nature18646. PMID   27409811.
  31. Abdullah A, Peeters A, de Courten M, Stoelwinder J (September 2010). "The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies". Diabetes Research and Clinical Practice. 89 (3): 309–19. doi:10.1016/j.diabres.2010.04.012. PMID   20493574.
  32. Pan A, Wang Y, Talaei M, Hu FB, Wu T (December 2015). "Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis". The Lancet. Diabetes & Endocrinology. 3 (12): 958–67. doi:10.1016/S2213-8587(15)00316-2. PMC   4656094 . PMID   26388413.
  33. 1 2 Malik VS, Popkin BM, Bray GA, Després JP, Hu FB (March 2010). "Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk". Circulation. 121 (11): 1356–64. doi:10.1161/CIRCULATIONAHA.109.876185. PMC   2862465 . PMID   20308626.
  34. Malik VS, Popkin BM, Bray GA, Després JP, Willett WC, Hu FB (November 2010). "Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis". Diabetes Care. 33 (11): 2477–83. doi:10.2337/dc10-1079. PMC   2963518 . PMID   20693348.
  35. Hu EA, Pan A, Malik V, Sun Q (March 2012). "White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review". BMJ. 344: e1454. doi:10.1136/bmj.e1454. PMC   3307808 . PMID   22422870.
  36. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT (July 2012). "Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy". Lancet. 380 (9838): 219–29. doi:10.1016/S0140-6736(12)61031-9. PMC   3645500 . PMID   22818936.
  37. Lind L, Lind PM (June 2012). "Can persistent organic pollutants and plastic-associated chemicals cause cardiovascular disease?". Journal of Internal Medicine. 271 (6): 537–53. doi:10.1111/j.1365-2796.2012.02536.x. PMID   22372998.
  38. 1 2 Herder C, Roden M (June 2011). "Genetics of type 2 diabetes: pathophysiologic and clinical relevance". European Journal of Clinical Investigation. 41 (6): 679–92. doi:10.1111/j.1365-2362.2010.02454.x. PMID   21198561.
  39. "Monogenic Forms of Diabetes: Neonatal Diabetes Mellitus and Maturity-onset Diabetes of the Young". National Diabetes Information Clearinghouse (NDIC). National Institute of Diabetes and Digestive and Kidney Diseases, NIH. March 2007. Archived from the original on 2008-07-04. Retrieved 2008-08-04.
  40. 1 2 Funnell MM, Anderson RM (2008). "Influencing self-management: from compliance to collaboration". In Feinglos MN, Bethel MA (eds.). Type 2 diabetes mellitus: an evidence-based approach to practical management. Contemporary endocrinology. Totowa, NJ: Humana Press. p. 462. ISBN   978-1-58829-794-5. OCLC   261324723.
  41. Izzedine H, Launay-Vacher V, Deybach C, Bourry E, Barrou B, Deray G (November 2005). "Drug-induced diabetes mellitus". Expert Opinion on Drug Safety. 4 (6): 1097–109. doi:10.1517/14740338.4.6.1097. PMID   16255667.
  42. Sampson UK, Linton MF, Fazio S (July 2011). "Are statins diabetogenic?". Current Opinion in Cardiology. 26 (4): 342–7. doi:10.1097/HCO.0b013e3283470359. PMC   3341610 . PMID   21499090.
  43. Saad F, Gooren L (March 2009). "The role of testosterone in the metabolic syndrome: a review". The Journal of Steroid Biochemistry and Molecular Biology. 114 (1–2): 40–3. doi:10.1016/j.jsbmb.2008.12.022. PMID   19444934.
  44. Farrell JB, Deshmukh A, Baghaie AA (2008). "Low testosterone and the association with type 2 diabetes". The Diabetes Educator. 34 (5): 799–806. doi: 10.1177/0145721708323100 . PMID   18832284.
  45. Diabetes mellitus a guide to patient care. Philadelphia: Lippincott Williams & Wilkins. 2007. p. 15. ISBN   978-1-58255-732-8.
  46. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation (PDF). Geneva: World Health Organization. 2006. p. 21. ISBN   978-92-4-159493-6.
  47. Vijan, S (March 2010). "Type 2 diabetes". Annals of Internal Medicine . 152 (5): ITC31-15. doi:10.7326/0003-4819-152-5-201003020-01003. PMID   20194231.
  48. World Health Organization. "Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus". Archived from the original on 2007-05-29. Retrieved 2007-05-29.
  49. 1 2 3 "International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes". Diabetes Care. 32 (7): 1327–34. July 2009. doi:10.2337/dc09-9033. PMC   2699715 . PMID   19502545.
  50. "Diagnosis and classification of diabetes mellitus". Diabetes Care. 33 Suppl 1 (Supplement_1): S62–9. January 2010. doi:10.2337/dc10-S062. PMC   2797383 . PMID   20042775.
  51. "Diagnosis and classification of diabetes mellitus". Diabetes Care. 35 Suppl 1 (Suppl 1): S64–71. January 2012. doi:10.2337/dc12-s064. PMC   3632174 . PMID   22187472.
  52. Kumar, Vinay; Fausto, Nelson; Abbas, Abul K.; Cotran, Ramzi S.; Robbins, Stanley L. (2005). Robbins and Cotran Pathologic Basis of Disease (7th ed.). Philadelphia, Pa.: Saunders. pp. 1194–95. ISBN   978-0-7216-0187-8.
  53. Diabetes mellitus a guide to patient care. Philadelphia: Lippincott Williams & Wilkins. 2007. p. 201. ISBN   978-1-58255-732-8.
  54. Vivian EM, Blackorbay B (2013). "Chapter 13: Endocrine Disorders". In Lee M (ed.). Basic Skills in Interpreting Laboratory Data (5th ed.). Bethesda, MD: American Society of Health-System Pharmacists. ISBN   978-1-58528-345-3. OCLC   859778842.
  55. 1 2 Valdez R (July 2009). "Detecting undiagnosed type 2 diabetes: family history as a risk factor and screening tool". Journal of Diabetes Science and Technology. 3 (4): 722–6. doi:10.1177/193229680900300417. PMC   2769984 . PMID   20144319.
  56. 1 2 Selph S, Dana T, Blazina I, Bougatsos C, Patel H, Chou R (June 2015). "Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 162 (11): 765–76. doi: 10.7326/M14-2221 . PMID   25867111.
  57. 1 2 "Archived: Diabetes Mellitus (Type 2) in Adults: Screening". U.S. Preventive Services Task Force. June 2008. Archived from the original on 2014-02-07. Retrieved 2014-03-16.
  58. Siu AL (December 2015). "Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement". Annals of Internal Medicine. 163 (11): 861–8. doi:10.7326/M15-2345. PMID   26501513.
  59. "Draft Recommendation Statement Screening for Abnormal Glucose and Type 2 Diabetes Mellitus". U.S. Preventive Services Task Force. Archived from the original on 9 October 2014. Retrieved 7 October 2014.
  60. 1 2 "Standards of medical care in diabetes--2015: summary of revisions". Diabetes Care. 38 Suppl (38): S4. January 2015. doi:10.2337/dc15-S003. PMID   25537706.
  61. Raina Elley C, Kenealy T (December 2008). "Lifestyle interventions reduced the long-term risk of diabetes in adults with impaired glucose tolerance". Evidence-Based Medicine. 13 (6): 173. doi:10.1136/ebm.13.6.173. PMID   19043031.
  62. Orozco LJ, Buchleitner AM, Gimenez-Perez G, Roqué I, Figuls M, Richter B, Mauricio D (July 2008). Mauricio D (ed.). "Exercise or exercise and diet for preventing type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews (3): CD003054. doi:10.1002/14651858.CD003054.pub3. PMID   18646086.
  63. 1 2 Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C (October 2013). "Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis". Annals of Internal Medicine. 159 (8): 543–51. doi:10.7326/0003-4819-159-8-201310150-00007. PMID   24126648.
  64. O'Gorman DJ, Krook A (September 2011). "Exercise and the treatment of diabetes and obesity". The Medical Clinics of North America. 95 (5): 953–69. doi:10.1016/j.mcna.2011.06.007. PMID   21855702.
  65. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman JL, Delwiche K, Iannarone ML, Moyer ML, Cercy K, Vos T, Murray CJ, Forouzanfar MH (August 2016). "Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013". BMJ. 354: i3857. doi: 10.1136/bmj.i3857 . PMC   4979358 . PMID   27510511.
  66. Nield L, Summerbell CD, Hooper L, Whittaker V, Moore H (July 2008). Nield L (ed.). "Dietary advice for the prevention of type 2 diabetes mellitus in adults". The Cochrane Database of Systematic Reviews (3): CD005102. doi:10.1002/14651858.CD005102.pub2. hdl:10149/92337. PMID   18646120. (Retracted, see doi:10.1002/14651858.cd005102.pub3. If this is an intentional citation to a retracted paper, please replace {{Retracted}} with {{Retracted |intentional=yes}}.)
  67. Carter P, Gray LJ, Troughton J, Khunti K, Davies MJ (August 2010). "Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis". BMJ. 341: c4229. doi:10.1136/bmj.c4229. PMC   2924474 . PMID   20724400.
  68. Xi B, Li S, Liu Z, Tian H, Yin X, Huai P, Tang W, Zhou D, Steffen LM (2014). "Intake of fruit juice and incidence of type 2 diabetes: a systematic review and meta-analysis". PloS One. 9 (3): e93471. doi:10.1371/journal.pone.0093471. PMC   3969361 . PMID   24682091.
  69. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L (February 2019). "Carbohydrate quality and human health: a series of systematic reviews and meta-analyses". Lancet. 393 (10170): 434–445. doi:10.1016/S0140-6736(18)31809-9. PMID   30638909.
  70. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, Booker L, Yazdi H (August 2005). "Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose" (PDF). Evidence Report/Technology Assessment (128): 1–11. PMC   4780988 . PMID   16194123. Archived from the original (PDF) on 2008-09-10.
  71. Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, Wei J, Narayan KM, Ali MK (December 2017). "Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials". JAMA Internal Medicine. 177 (12): 1808–1817. doi:10.1001/jamainternmed.2017.6040. PMC   5820728 . PMID   29114778.
  72. Seida JC, Mitri J, Colmers IN, Majumdar SR, Davidson MB, Edwards AL, Hanley DA, Pittas AG, Tjosvold L, Johnson JA (October 2014). "Clinical review: Effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis". The Journal of Clinical Endocrinology and Metabolism. 99 (10): 3551–60. doi:10.1210/jc.2014-2136. PMC   4483466 . PMID   25062463.
  73. 1 2 "Type 2 diabetes: The management of type 2 diabetes". May 2009. Archived from the original on 2015-05-22.
  74. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A (February 2015). "Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis". JAMA. 313 (6): 603–15. doi:10.1001/jama.2014.18574. PMID   25668264.
  75. McBrien K, Rabi DM, Campbell N, Barnieh L, Clement F, Hemmelgarn BR, Tonelli M, Leiter LA, Klarenbach SW, Manns BJ (September 2012). "Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis". Archives of Internal Medicine. 172 (17): 1296–303. doi:10.1001/archinternmed.2012.3147. PMID   22868819.
  76. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C (July 2011). "Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials". BMJ. 343: d4169. doi:10.1136/bmj.d4169. PMC   3144314 . PMID   21791495.
  77. Webster MW (July 2011). "Clinical practice and implications of recent diabetes trials". Current Opinion in Cardiology. 26 (4): 288–93. doi:10.1097/HCO.0b013e328347b139. PMID   21577100.
  78. 1 2 3 4 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (March 2015). "Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes". Diabetologia. 58 (3): 429–42. doi:10.1007/s00125-014-3460-0. PMID   25583541.
  79. Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA (April 2018). "Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians". Annals of Internal Medicine. 168 (8): 569–576. doi:10.7326/M17-0939. PMID   29507945.
  80. Makam AN, Nguyen OK (January 2017). "An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment". Circulation. 135 (2): 180–195. doi:10.1161/CIRCULATIONAHA.116.022622. PMC   5502688 . PMID   28069712.
  81. 1 2 3 Simpson TC, Weldon JC, Worthington HV, Needleman I, Wild SH, Moles DR, Stevenson B, Furness S, Iheozor-Ejiofor Z (November 2015). "Treatment of periodontal disease for glycaemic control in people with diabetes mellitus". The Cochrane Database of Systematic Reviews (11): CD004714. doi:10.1002/14651858.CD004714.pub3. PMID   26545069.
  82. Smith AD, Crippa A, Woodcock J, Brage S (December 2016). "Physical activity and incident type 2 diabetes mellitus: a systematic review and dose-response meta-analysis of prospective cohort studies". Diabetologia. 59 (12): 2527–2545. doi:10.1007/s00125-016-4079-0. PMC   6207340 . PMID   27747395.
  83. Thomas DE, Elliott EJ, Naughton GA (July 2006). "Exercise for type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews (3): CD002968. doi:10.1002/14651858.CD002968.pub2. PMID   16855995.
  84. 1 2 Zanuso S, Jimenez A, Pugliese G, Corigliano G, Balducci S (March 2010). "Exercise for the management of type 2 diabetes: a review of the evidence" (PDF). Acta Diabetologica. 47 (1): 15–22. doi:10.1007/s00592-009-0126-3. PMID   19495557.
  85. 1 2 Davis N, Forbes B, Wylie-Rosett J (June 2009). "Nutritional strategies in type 2 diabetes mellitus". The Mount Sinai Journal of Medicine, New York. 76 (3): 257–68. doi:10.1002/msj.20118. PMID   19421969.
  86. Thomas D, Elliott EJ (January 2009). Thomas D (ed.). "Low glycaemic index, or low glycaemic load, diets for diabetes mellitus". The Cochrane Database of Systematic Reviews (1): CD006296. doi:10.1002/14651858.CD006296.pub2. PMID   19160276.
  87. Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, Accurso A, Frassetto L, Gower BA, McFarlane SI, Nielsen JV, Krarup T, Saslow L, Roth KS, Vernon MC, Volek JS, Wilshire GB, Dahlqvist A, Sundberg R, Childers A, Morrison K, Manninen AH, Dashti HM, Wood RJ, Wortman J, Worm N (January 2015). "Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base". Nutrition. 31 (1): 1–13. doi:10.1016/j.nut.2014.06.011. PMID   25287761.
  88. Clifton P (October 2017). "Assessing the evidence for weight loss strategies in people with and without type 2 diabetes". World Journal of Diabetes. 8 (10): 440–454. doi:10.4239/wjd.v8.i10.440. PMC   5648990 . PMID   29085571.
  89. Glick-Bauer M, Yeh MC (October 2014). "The health advantage of a vegan diet: exploring the gut microbiota connection". Nutrients (Review). 6 (11): 4822–38. doi:10.3390/nu6114822. PMC   4245565 . PMID   25365383.
  90. Leach MJ, Kumar S (September 2012). "Cinnamon for diabetes mellitus". The Cochrane Database of Systematic Reviews (9): CD007170. doi:10.1002/14651858.CD007170.pub2. PMID   22972104.
  91. Attridge M, Creamer J, Ramsden M, Cannings-John R, Hawthorne K (September 2014). "Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews (9): CD006424. doi:10.1002/14651858.CD006424.pub3. PMID   25188210.
  92. Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF (July 2016). "Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis". JAMA. 316 (3): 313–24. doi: 10.1001/jama.2016.9400 . PMID   27434443.
  93. Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F, Cornu C (2012). Groop L (ed.). "Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials". PLoS Medicine. 9 (4): e1001204. doi:10.1371/journal.pmed.1001204. PMC   3323508 . PMID   22509138.
  94. Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K (April 2018). "Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis". JAMA. 319 (15): 1580–1591. doi:10.1001/jama.2018.3024. PMC   5933330 . PMID   29677303.
  95. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH (July 2007). Richter B (ed.). "Rosiglitazone for type 2 diabetes mellitus" (PDF). The Cochrane Database of Systematic Reviews (3): CD006063. doi:10.1002/14651858.CD006063.pub2. PMID   17636824.
  96. Chen X, Yang L, Zhai SD (December 2012). "Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies". Chinese Medical Journal. 125 (23): 4301–6. PMID   23217404.
  97. Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF (December 2012). Strippoli GF (ed.). "Antihypertensive agents for preventing diabetic kidney disease". The Cochrane Database of Systematic Reviews. 12: CD004136. doi:10.1002/14651858.CD004136.pub3. PMID   23235603.
  98. 1 2 Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J (May 2014). "Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis". JAMA Internal Medicine. 174 (5): 773–85. doi:10.1001/jamainternmed.2014.348. PMID   24687000.
  99. Brunström M, Carlberg B (February 2016). "Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses". BMJ. 352: i717. doi: 10.1136/bmj.i717 . PMC   4770818 . PMID   26920333.
  100. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH (July 2011). Simon AC (ed.). "Insulin detemir versus insulin glargine for type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews (7): CD006383. doi:10.1002/14651858.CD006383.pub2. PMID   21735405.
  101. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S (July 2010). "Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation". Health Technology Assessment. 14 (36): 1–248. doi:10.3310/hta14360. PMID   20646668.
  102. Mirhosseini N, Vatanparast H, Mazidi M, Kimball SM (September 2017). "The Effect of Improved Serum 25-Hydroxyvitamin D Status on Glycemic Control in Diabetic Patients: A Meta-Analysis". The Journal of Clinical Endocrinology and Metabolism. 102 (9): 3097–3110. doi:10.1210/jc.2017-01024. PMID   28957454.
  103. Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ (September 2009). "The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation". Health Technology Assessment. 13 (41): 1–190, 215–357, iii–iv. doi:10.3310/hta13410. PMID   19726018.
  104. Frachetti KJ, Goldfine AB (April 2009). "Bariatric surgery for diabetes management". Current Opinion in Endocrinology, Diabetes and Obesity. 16 (2): 119–24. doi:10.1097/MED.0b013e32832912e7. PMID   19276974.
  105. 1 2 Schulman AP, del Genio F, Sinha N, Rubino F (September–October 2009). ""Metabolic" surgery for treatment of type 2 diabetes mellitus". Endocrine Practice. 15 (6): 624–31. doi:10.4158/EP09170.RAR. PMID   19625245.
  106. Colucci RA (January 2011). "Bariatric surgery in patients with type 2 diabetes: a viable option". Postgraduate Medicine. 123 (1): 24–33. doi:10.3810/pgm.2011.01.2242. PMID   21293081.
  107. Dixon JB, le Roux CW, Rubino F, Zimmet P (June 2012). "Bariatric surgery for type 2 diabetes". Lancet. 379 (9833): 2300–11. doi:10.1016/S0140-6736(12)60401-2. PMID   22683132.
  108. Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, Del Prato S, Ji L, Sadikot SM, Herman WH, Amiel SA, Kaplan LM, Taroncher-Oldenburg G, Cummings DE (June 2016). "Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations". Diabetes Care. 39 (6): 861–77. doi:10.2337/dc16-0236. PMID   27222544.
  109. Abate N, Chandalia M (2001). "Ethnicity and type 2 diabetes: focus on Asian Indians". Journal of Diabetes and its Complications. 15 (6): 320–7. doi:10.1016/S1056-8727(01)00161-1. PMID   11711326.
  110. Carulli L, Rondinella S, Lombardini S, Canedi I, Loria P, Carulli N (November 2005). "Review article: diabetes, genetics and ethnicity". Alimentary Pharmacology & Therapeutics. 22 Suppl 2: 16–9. doi:10.1111/j.1365-2036.2005.02588.x. PMID   16225465.
  111. Wild S, Roglic G, Green A, Sicree R, King H (May 2004). "Global prevalence of diabetes: estimates for the year 2000 and projections for 2030". Diabetes Care. 27 (5): 1047–53. doi:10.2337/diacare.27.5.1047. PMID   15111519.
  112. 1 2 3 4 5 6 7 8 9 Zajac J, Shrestha A, Patel P, Poretsky L (2009). "The Main Events in the History of Diabetes Mellitus". In Poretsky L (ed.). Principles of diabetes mellitus (2nd ed.). New York: Springer. pp. 3–16. ISBN   978-0-387-09840-1. OCLC   663097550.
External resources